Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.
Saved in:
| Title: | Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. |
|---|---|
| Authors: | Magnolo, Nina1 (AUTHOR) nina.magnolo@ukmuenster.de, Soung, Jennifer2,3 (AUTHOR), Frew, John4,5,6 (AUTHOR), Costanzo, Antonio7,8 (AUTHOR), Ruiz-Santiago, Hiram9 (AUTHOR), Eyerich, Kilian10 (AUTHOR), Llamas-Velasco, Mar11 (AUTHOR), Bukhalo, Michael12 (AUTHOR), Sivamani, Raja K.13 (AUTHOR), Moore, Angela14,15,16 (AUTHOR), Wu, Tianshuang17 (AUTHOR), Xie, Jiaheng17 (AUTHOR), Patel, Manish17 (AUTHOR), Ashley, Doug17 (AUTHOR), Kaplan, Blair17 (AUTHOR), Stakias, Vassilis17 (AUTHOR), Espaillat, Ramon17 (AUTHOR), Warren, Richard B.18 (AUTHOR) |
| Source: | Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3415-3429. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
